Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): an extension study.

René Adam, MD, PhD¹, Vincent Karam, PhD¹, Valérie Cailliez¹, Pavel Trunečka, MD, PhD², Didier Samuel, MD, PhD¹, Giuseppe Tisone, MD, PhD³, Petr Němec, MD, PhD⁴, Olivier Soubrane, MD, PhD⁵, Stefan Schneeberger, MD, PhD⁶, Bruno Gridelli, MD, PhD⁷, Wolf O. Bechstein, MD, PhD⁸, Andrea Risaliti, MD, PhD⁹, Pal-Dag Line, MD, PhD¹⁰, Marco Vivarelli, MD, PhD¹¹, Massimo Rossi, MD, PhD¹², Jacques Pirenne, MD, PhD¹³, Jorgen L. Klempnauer, MD, PhD¹⁴, Aleh Rummo, MD, PhD¹⁵, Fabrizio Di Benedetto, MD, PhD¹⁶, Krzysztof Zieniewicz, MD, PhD¹⁷, Roberto Troisi, MD, PhD¹⁸, Andreas Paul, MD, PhD¹⁹, Toomas Vali, MD, PhD²⁰, Otto Kollmar, MD, PhD²¹, Karim Boudjema, MD, PhD²², Emir Hoti, MD, PhD²³, Michele Colledan, MD, PhD²⁴, Johan Pratschke, MD, PhD²⁵, Hauke Lang, MD, PhD²⁶, Irinel Popescu, MD, PhD²⁷, Bo-Goran Ericzon, MD, PhD²⁸, Kestutis Strupas, MD, PhD²⁹, Paolo De Simone, MD, PhD³⁰, Eberhard Kochs, MD, PhD³¹, Bruno Heyd, MD, PhD³², Jean Gugenheim, MD, PhD³³, Antonio D. Pinna, MD, PhD³⁴, William Bennet, MD, PhD³⁵, Mirjalal Kazimi, MD, PhD³⁶, Philippe Bachellier, MD, PhD³⁷, Stephen J. Wigmore, MD, PhD³⁸, Allan Rasmussen, MD, PhD³⁹, Pierre-Alain Clavien, MD, PhD⁴⁰, Ernest Hidalgo, MD, PhD⁴¹, John G. O'Grady, MD, PhD⁴², Frausto Zamboni, MD, PhD⁴³, Murat Kilic, MD, PhD⁴⁴, Christophe Duvoux, MD, PhD⁴⁵, and all contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)

¹Hepato-Biliary Center, AP-HP Paul Brousse Hospital, University of Paris-Sud, Inserm U935, Villejuif, France; ²Transplantcenter, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; ³Liver Transplant Unit, Tor Vergata Polyclinic, University

of Rome Tor Vergata, Rome, Italy; ⁴Center of Cardiovascular Surgery and Transplantation, Brno, Czech Republic; ⁵Department of Digestive Surgery, AP-HP Beaujon Hospital, Clichy, France; ⁶Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria; ⁷Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Palermo, Italy; ⁸Department of General and Visceral Surgery, Goethe University Hospital and Clinics, Frankfurt, Germany; ⁹Department of Surgery, Liver Transplant Unit, University Hospital Udine, Udine, Italy; ¹⁰Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; ¹¹Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy; ¹²Department of General Surgery, Organ Transplant Unit “Paride Stefanini”, Umberto 1 Policlinico of Rome, Rome, Italy; ¹³Abdominal Transplant Surgery, University Hospital Leuven, Leuven, Belgium; ¹⁴Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany; ¹⁵Republican Scientific and Practical Center (RSPC) for Organ and Tissue Transplantation, Minsk, Belarus; ¹⁶Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy; ¹⁷Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; ¹⁸Department of General Hepato-Biliary and Liver Transplantation Surgery, Ghent University Hospital Medical School, Belgium; ¹⁹Department of General and Transplant Surgery, University Hospital Essen, Essen, Germany; ²⁰Surgery Clinic, Tartu University Hospital, Tartu, Estonia; ²¹Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany; ²²Department of Visceral Surgery, University Hospital Rennes, Pontchaillou Hospital, Rennes, France; ²³Liver Unit, St Vincent’s Hospital, Dublin, Ireland; ²⁴Department of Surgery, Pope John XXIII Hospital, Bergamo, Italy; ²⁵Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-

Klinikum (CVK), Berlin, Germany; ²⁶General, Visceral and Transplantation Surgery Clinic, Johannes Gutenberg University Mainz, Mainz, Germany; ²⁷Department of Surgery and Liver Transplantation, Fundeni Clinical Institute, University of Medicine “Carol Davila”, Bucharest, Romania; ²⁸Department of Transplantation Surgery, Karolinska University Hospital, Huddinge, Sweden; ²⁹Department for Gastroenterology, Nephrology and Surgery, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; ³⁰Hepatobiliary Surgery and Liver Transplantation Unit, University of Pisa Medical School Hospital, Pisa, Italy; ³¹Surgical Clinic and Polyclinic, University Hospital Klinikum rechts der Isar Munich, Munich, Germany; ³²Department of Visceral Surgery, University Hospital Besançon, University of Franche-Comté, Besançon, France; ³³Department of Digestive Surgery, Archet 2 Hospital, Nice, France; ³⁴University of Bologna, Transplant and HPB Institute, Bologna, Italy; ³⁵Surgery Department, Transplantation and Liver Surgery Unit, Sahlgrenska University Hospital, Gothenburg, Sweden; ³⁶Surgery and Organ Transplantation Center, Central Hospital Of Oil Workers, Baku, Azerbaijan; ³⁷Department of Surgery, Hospital Hautepierre, University Hospitals of Strasbourg, Strasbourg, France; ³⁸Liver Transplantation Unit, University of Edinburgh Royal Infirmary, Edinburgh, United Kingdom; ³⁹Department for Surgery and Transplantation, University Hospital Copenhagen, Copenhagen, Denmark; ⁴⁰Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland; ⁴¹St James and Seacroft University Hospital, Leeds, United Kingdom; ⁴²Liver Unit, King’s College Hospital, London, United Kingdom; ⁴³Department of General Surgery and Transplantation, Hospital G. Brotzu, Cagliari, Italy; ⁴⁴Kent Hospital, Izmir, Turkey; ⁴⁵Department of Hepatology and Gastroenterology, University Hospital of Henri-Mondor, Creteil, France

Correspondence information: Prof. René Adam, Centre Hépatobiliaire, Hôpital Paul Brousse, Avenue Paul Vaillant Couturier, 94804 Villejuif, France. rene.adam@aphp.fr

AUTHORSHIP PAGE

René Adam: Participated in research design, participated in the writing of the paper, participated in data analysis

Vincent Karam: Participated in research design, participated in the writing of the paper, participated in data analysis

Valérie Cailliez: Participated in research design, participated in data analysis

Pavel Trunečka: Participated in the performance of the research

Didier Samuel: Participated in the performance of the research

Giuseppe Tisone: Participated in the performance of the research

Petr Němec: Participated in the performance of the research

Olivier Soubrane: Participated in the performance of the research

Stefan Schneeberger: Participated in the performance of the research

Bruno Gridelli: Participated in the performance of the research

Wolf O. Bechstein: Participated in the performance of the research

Andrea Risaliti: Participated in the performance of the research

Pal-Dag Line: Participated in the performance of the research

Marco Vivarelli: Participated in the performance of the research

Massimo Rossi: Participated in the performance of the research

Jacques Pirenne: Participated in the performance of the research

Jurgen L. Klempnauer: Participated in the performance of the research

Aleh Rummo: Participated in the performance of the research

Fabrizio Di Benedetto: Participated in the performance of the research

Krzysztof Zieniewicz: Participated in the performance of the research

Roberto Troisi: Participated in the performance of the research

Andreas Paul: Participated in the performance of the research

Toomas Vali: Participated in the performance of the research

Otto Kollmar: Participated in the performance of the research

Karim Boudjema: Participated in the performance of the research

Emir Hoti: Participated in the performance of the research

Michele Colledan: Participated in the performance of the research

Johan Pratschke: Participated in the performance of the research

Hauke Lang: Participated in the performance of the research

Irinel Popescu: Participated in the performance of the research

Bo-Goran Ericzon: Participated in the performance of the research

Kestutis Strupas: Participated in the performance of the research

Paolo De Simone: Participated in the performance of the research

Eberhard Kochs: Participated in the performance of the research

Bruno Heyd: Participated in the performance of the research

Jean Gugenheim: Participated in the performance of the research

Antonio D. Pinna: Participated in the performance of the research

William Bennet: Participated in the performance of the research

Mirjalal Kazimi: Participated in the performance of the research

Philippe Bachellier: Participated in the performance of the research

Stephen J. Wigmore: Participated in the performance of the research

Allan Rasmussen: Participated in the performance of the research

Pierre-Alain Clavien: Participated in the performance of the research

Ernest Hidalgo: Participated in the performance of the research

John G. O'Grady: Participated in the performance of the research

Frausto Zamboni: Participated in the performance of the research

Murat Kilic: Participated in the performance of the research

Christophe Duvoux: Participated in the performance of the research

Disclosure:

R. Adam, V. Karam, V. Cailliez, G. Tisone, O. Soubrane, B. Gridelli, P. D. Line, M. Rossi, J. Pirenne, O. O. Rummo, F. Di Benedetto, K. Zieniewicz, R. Troisi, A. Paul, T. Vali, O. Kollmar, K. Boudjema, J. Pratschke, J. Gugenheim, A. D. Pinna, W. Bennet, P. Bachellier, S. J. Wigmore, A. Rasmussen, P. A. Clavien, E. Hidalgo, and F. Zamboni declare no conflict of interests with respect to this manuscript. P. Trunečka has received speaker honorarium from Pfizer and has been involved in advisory boards and received consultancy agreements from Astellas. D. Samuel has received consultant fees from Astellas, Novartis and Roche. P. Němec has received speaker honoraria from Astellas and Novartis. W. O. Bechstein has received honoraria and served on advisory boards for Astellas. M. Vivarelli has received honorarium for an advisory board for Novartis. J. Klempnauer has received support from Astellas, Novartis, Roche, BMS and Genzyme. M. Colledan has received honorarium for an advisory board for Novartis. B. G. Ericzon has received speaker honorarium from Pfizer, Astellas and Novartis. P. De Simone has received speaker fees and served as an advisory board member for Astellas. C. Duvoux has received grants from Astellas, grants from Novartis, grants and other from Chiesi, personal fees from Sandoz, and non financial support from Biotest.

Fundings: The ELTR is supported by a grant from Astellas, Novartis, and Institut Georges Lopez, and logistic support from the Paul Brousse Hospital (Assistance Publique – Hôpitaux de Paris).

ABBREVIATION PAGE

BMI, Body mass index

CI, confidence interval

ELTR, European Liver Transplant Registry

HBsAg, HBV surface antigen

HBV, Hepatitis B virus

HCC, Hepatocellular carcinoma

HCV, Hepatitis C virus

HIV, Human immunodeficiency virus

HTK, Histidine Tryptophan Ketoglutarate

IR, immediate-release

mITT, Modified intent-to-treat

MELD, Model for End-stage Liver Disease

MMF, Mycophenolate mofetil

PR, prolonged-release

SD, Standard deviation

UNOS, United Network for Organ Sharing

ABSTRACT

Background: We compare, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release-tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected 2008–2016, in an extension of our previously-published study.

Methods: Patients with <1 month follow-up were excluded; patients were propensity score-matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8-years post transplantation; graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13,088 patients were included from 44 European centers; propensity-score-matched analyses comprised 3006 patients (PR-T: n=1002; IR-T: n=2004).

Results: In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk-ratio: 1.49; $p=0.0038$) and patient survival (risk-ratio: 1.40; $p=0.0215$). There was improvement with PR-T versus IR-T in graft survival (83% vs 77% at 4 years, respectively; $p=0.005$) and patient survival (85% vs 80%; $p=0.017$). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate versus patients receiving IR-T at last follow-up ($p<0.001$), or started and maintained on PR-T ($p=0.019$). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T.

Conclusion: PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients versus IR-T.

Introduction

Significant advances in the success of liver transplantation have been made over the last two decades, despite the increasing use of extended-criteria donors.¹ However, while 1-year graft and patient survival rates in Europe are 77% and 83%, respectively, after a first liver transplantation, 10-year graft and patient survival rates remain lower, at 54% and 61%.²

Improving long-term liver transplant outcomes has, therefore, become a primary focus of the transplant community. Many factors can negatively influence outcomes in liver transplantation, including high Model for End-stage Liver Disease (MELD) scores and the viral status of the recipient (for example, hepatitis C virus (HCV) infection).^{3,4} Non adherence to immunosuppressive therapy, and high intra-patient variability of drug exposure, could also potentially reduce long-term transplant outcomes.⁵⁻¹⁰

Tacrolimus is now the cornerstone of immunosuppression after liver transplantation.¹¹ A once-daily, prolonged-release (PR) formulation of tacrolimus was licensed in Europe in 2007, for use in adult kidney or liver transplant recipients.¹² PR tacrolimus has demonstrated comparable efficacy to IR tacrolimus in clinical studies with de novo liver transplant recipients, and is efficacious following conversion of stable liver transplant recipients from IR to PR tacrolimus.¹³⁻¹⁶ However, it is thought that the PR formulation may offer advantages over twice-daily, immediate-release (IR) tacrolimus, by reducing non adherence to immunosuppressant medication, and by decreasing inpatient variability in tacrolimus exposure.¹⁷⁻¹⁹ As both of these parameters have been associated with poor liver transplant outcomes,^{8,20} treatment with PR tacrolimus has the potential to improve long-term outcomes for liver recipients, compared with the IR formulation. However, as clinical trials are of relatively short duration, there is a need for data to assess the effect of PR tacrolimus on long-term outcomes in liver transplantation. In this regard, registry studies can provide prospective and retrospective long-term data.

The impact of PR versus IR tacrolimus on long-term graft and patient survival was recently assessed using data from the European Liver Transplant Registry (ELTR) in 528 and 3839 patients receiving PR or IR tacrolimus, respectively.²¹ The study was conducted at 21 European centers between 2008 and 2012.²¹ Multivariable analyses showed that the use of IR tacrolimus was associated with a higher risk of graft loss (risk ratio: 1.81; p=0.001) and patient death (risk ratio: 1.72; p=0.004) compared with PR tacrolimus.²¹ We report here an analysis of up to 8-year data, collected between 2008 and 2016, in an extension of the previously-published study, with the aim of comparing long-term liver transplant outcomes with PR versus IR tacrolimus-based immunosuppression. We also studied the outcome of converting patients from one formulation of the drug to the other, during the post transplantation follow-up period.

Materials and Methods

This was a retrospective analysis of primary liver transplant patients receiving PR tacrolimus (Advagraf™, Astellas Pharma Europe BV, Netherlands) and IR tacrolimus in the ELTR database, as previously described.²¹ The ELTR currently represents liver transplant data from 174 transplant centers across Europe. Data from participating centers are collected on a voluntary basis at regular intervals using a two-part, standardized questionnaire designed by the ELTR Coordinating Committee, to capture information on donors and recipients, as described previously.²¹ The methods used to populate the registry and obtain the data have been described elsewhere.^{22–24} In order to prevent center bias, only the 44 centers who used both PR and IR tacrolimus at the time of the study were eligible for inclusion in this analysis.

Inclusion criteria

Data were collected prospectively from patients (≥18 years old) who underwent their first liver transplant between January 2008 and June 2016 from contributing centers across Europe. All patients included in this study received PR or IR tacrolimus, with or without

concomitant immunosuppressants (including induction agents) within the first month after liver transplantation.

Clinical efficacy measures

Efficacy measures were analyzed using the modified intent-to-treat (mITT) population, which excluded all patients who had less than 1 month of follow-up after transplantation. This strategy aimed to avoid the potential impact of early post operative complications not associated with the immunosuppressive regimen. The clinical efficacy measures included univariate and multivariate analyses of the risk factors influencing graft and patient survival; Kaplan–Meier estimates of the incidence of graft and patient survival stratified by PR and IR tacrolimus-based immunosuppression; and causes of graft loss and mortality. Treatment groups were stratified by PR or IR tacrolimus treatment during the first month after transplantation, and patients remained in these allocated groups, regardless of any changes in immunosuppression during follow-up. However, cross-over changes from IR to PR and vice versa after 1 month of therapy, regardless of the date of change(s), were considered in order to measure their impact on graft and patient outcomes. The maintenance immunosuppression data considered in this study were those collected at the last patient follow-up. The number of patients needed to treat with PR versus IR tacrolimus in order to avoid one graft loss in 4 years was calculated. In order to adjust for the number of patients at risk over the enrollment time between 2008 and 2016 (less patients at risk in the PR than IR tacrolimus group at 4 years owing to the gradual increase in the use of PR tacrolimus), the era of transplantation was added to the univariate and multivariate analyses.

Propensity score matching

In order to account for differences in donor and recipient baseline characteristics between groups when estimating the effect of treatment on outcomes, the clinical efficacy measures were repeated on a propensity score-matched population. PR and IR tacrolimus groups were

paired on a 1:2 ratio according to 18 items with similar values. The propensity score was based on recipient age (≥ 60 versus < 60 years), donor age (≥ 60 versus < 60 years), full-size organ from a donor after brain death versus all other alternative grafts (living donor, domino, donation after circulatory death, or split grafts from a donor after brain death), MELD score (> 24 versus ≤ 24), recipient hepatitis B virus surface antigen (HBsAg), hepatocellular carcinoma (HCC), presence of severe ascites before liver transplantation, United Network for Organ Sharing (UNOS) status (3–4 versus 1–2), total ischemia time (≥ 6 versus < 6 hours), graft preservation solution Histidine Tryptophan Ketoglutarate (HTK) versus all other solutions (University Wisconsin [UW], Celsior, IGL-1, Marshall, Ringer, SCOT, or other) and administration of other immunosuppressive medications early post transplantation (corticosteroids, mycophenolate mofetil (MMF), ciclosporin, basiliximab, daclizumab, sirolimus, everolimus, azathioprine). For continuous variables that were converted to discontinuous variables in the model (eg, donor age, recipient age, MELD score) the values that were the most discriminant between PR and IR tacrolimus were selected as cut-offs, based on calculation of Chi square and odds ratios (data not shown). All unmatched units in the PR and IR tacrolimus groups were excluded from the propensity score-matched population.

Statistical analyses

Statistical analyses were conducted as previously described.²¹ A univariate Cox regression analysis was performed to evaluate the risk factors influencing graft and patient survival after liver transplantation. Data from the univariate analyses were reported using log-rank p values, with $p < 0.05$ considered to be statistically significant. A Cox proportional hazards regression evaluation ($p < 0.15$) was used in a multivariate model to assess the impact of donor and recipient variables on graft and patient survival. Patients with missing data on the ELTR questionnaire were excluded from the multivariate analyses. Kaplan–Meier analyses were

used to estimate graft and patient survival stratified by treatment group; statistical analyses were performed using the log-rank test ($p < 0.05$). Analyses were performed using SAS[®] Enterprise Guide version 5.1 (SAS Institute Inc., Cary, North Carolina, USA).

Results

Donor and recipient characteristics and demographics

Patient population

In the initial ELTR study, 4367 primary liver transplant recipients (PR tacrolimus, $n=528$; IR tacrolimus, $n=3839$) were included in the analysis, between 2008 and 2012.²¹ In this extension analysis, 13,088 primary liver transplant recipients were included (**Figure 1**). All patients received either PR tacrolimus ($n=1762$) or IR tacrolimus ($n=11,326$). Since PR tacrolimus was licensed for use in 2007,¹² the proportion of patients who received PR tacrolimus during Month 1 gradually increased over enrolment (between 2008 and 2016).

Baseline characteristics

Baseline characteristics of donors and recipients are presented in **Table 1**. Mean recipient age was greater in the PR versus IR tacrolimus group (52.1 ± 18.7 vs 51.8 ± 18.1 years, respectively; $p < 0.001$). The other main characteristics and their differences between groups are shown in **Table 1**.

Concomitant medications

Baseline tacrolimus-associated induction immunosuppressive medications were different in the two groups: Corticosteroids (69.2% vs 61.4%, $p < 0.001$), everolimus (7.5% vs 2.5%, $p < 0.001$), MMF (75.1% vs 55.8%, $p < 0.001$) and daclizumab (1.8% vs 0.8%, $p < 0.001$) were more frequently combined with PR tacrolimus. Azathioprine (3.2% vs 0.5%, $p < 0.001$), ciclosporin (1.6% vs 0.2%, $p < 0.001$), basiliximab (25.4% vs 22.0%, $p = 0.002$) and sirolimus (0.6% vs 0.2%, $p = 0.026$) were more frequently combined with IR tacrolimus. However

propensity score matching has been used to account for these baseline differences (see below).

Analyses of patients with ≥ 1 month of follow-up

Univariate analyses

In the univariate analysis, IR tacrolimus during the first month post transplantation was identified as a significant risk factor for inferior graft survival ($p < 0.001$) and patient survival ($p = 0.003$) over 8 years. Other factors that significantly contributed to reduced long-term graft and patient survival are listed in **Table 2**.

Kaplan–Meier analyses

Kaplan–Meier analysis demonstrated significantly improved graft and patient survival over 4 years with PR versus IR tacrolimus (84% vs 79%, $p < 0.001$ and 85% vs 81%, $p = 0.003$, respectively) (**Figure 2**). At Year 4, a 5% and 4% improvement in graft and patient survival, respectively, was observed in the PR versus IR tacrolimus group.

Propensity score-matched analyses

The propensity score-matched analysis was performed on 3,006 patients (PR tacrolimus, $n = 1,002$; IR tacrolimus, $n = 2,004$). Donor and recipient baseline characteristics were generally comparable between the two treatment groups for the propensity score-matched patients, especially for the concomitant immunosuppressive drugs combined with tacrolimus (**Table 1**).

Univariate and multivariate analyses

In the univariate analysis, the use of IR tacrolimus was a significant risk factor for reduced graft and patient survival ($p = 0.005$ and $p = 0.017$, respectively) in addition to other factors listed in **Table 3**. Long-term graft survival was significantly impacted by thirteen additional factors: donor age ≥ 50 years ($p < 0.001$), recipient age ≥ 50 years ($p = 0.006$), recipient dialysis twice in week prior to transplantation ($p = 0.016$), negative HBV delta ($p = 0.017$), positive

anti-HCV serology ($p<0.001$), positive HIV serology ($p=0.028$), positive HCV RNA ($p<0.001$), urgent liver transplant ($p=0.038$), UNOS status 1 or 2 ($p<0.001$), serum creatinine concentration ≥ 2 mg/dL ($p=0.01$), Milan criteria-out in patients with HCC ($p<0.001$), HCC with tumor size >50 mm ($p<0.001$) and heterotopic liver transplant ($p=0.003$).

Long-term patient survival was significantly impacted by fifteen other factors: donor age ≥ 50 years ($p<0.001$), presence of macro/micro-vesicular graft steatosis ($p=0.039$), male recipient ($p=0.021$), recipient age ≥ 50 years ($p=0.001$), recipient dialysis twice in week prior to transplantation ($p=0.006$), negative HBV delta ($p=0.025$), positive anti-HCV serology ($p<0.001$), positive HIV serology ($p=0.045$), positive HCV RNA ($p<0.001$), UNOS status 1 or 2 ($p<0.001$), serum creatinine concentration ≥ 2 mg/dL ($p=0.001$), cancer as main indication ($p=0.032$), Milan criteria-out in patients with HCC ($p<0.001$), HCC with tumor size >50 mm ($p<0.001$) and heterotopic liver transplant ($p=0.001$).

In the multivariate analysis (**Table 4**), the use of IR tacrolimus was a significant independent risk factor for reduced graft survival (risk ratio: 1.49; 95% confidence interval (CI): 1.14–1.96; $p=0.0038$) associated with five other factors: recipient positive anti-HCV serology (risk ratio: 2.05; 95% confidence interval (CI): 1.66–2.54; $p<0.001$), recipient age ≥ 50 years (risk ratio: 1.74; 95% confidence interval (CI): 1.43–2.11; $p<0.001$), UNOS status 1 or 2 (risk ratio: 1.69; 95% confidence interval (CI): 1.35–2.11; $p<0.001$), serum creatinine concentration ≥ 2 mg/dL (risk ratio: 1.66; 95% confidence interval (CI): 1.18–2.35; $p=0.004$) and donor age ≥ 50 years (risk ratio: 1.35; 95% confidence interval (CI): 1.09–1.66; $p=0.005$).

The use of IR tacrolimus was also a significant independent risk factor for reduced patient survival (risk ratio: 1.40; 95% CI: 1.05–1.86; $p=0.0215$) associated with six other factors: recipient positive anti-HCV serology (risk ratio: 1.91; 95% confidence interval (CI): 1.52–2.40; $p<0.001$), serum creatinine concentration ≥ 2 mg/dL (risk ratio: 1.90; 95% confidence interval (CI): 1.33–2.71; $p<0.001$), UNOS status 1 or 2 (risk ratio: 1.89; 95% confidence

interval (CI): 1.49–2.39; $p < 0.001$), recipient age ≥ 50 years (risk ratio: 1.74; 95% confidence interval (CI): 1.41–2.16; $p < 0.001$), HCC as primary or secondary disease (risk ratio: 1.35; 95% confidence interval (CI): 1.07–1.69; $p = 0.01$), and donor age ≥ 50 years (risk ratio: 1.33; 95% confidence interval (CI): 1.07–1.66; $p = 0.01$).

Kaplan–Meier analyses and number of patients needed to treat to avoid one graft loss

Kaplan–Meier analysis demonstrated significantly improved graft and patient survival over 4 years with PR versus IR tacrolimus (83% vs 77%, $p = 0.005$ and 85% vs 80%, $p = 0.017$, respectively) (**Figure 3**). At Year 4, a 6% and 5% improvement in graft and patient survival respectively, was observed in the PR versus IR tacrolimus group. The number of patients needed to treat with PR versus IR tacrolimus in order to avoid one graft loss in 4 years was 14.3 patients (95% CI: 9.7–27.3).

Analysis of crossover groups

In the non converted patients over the study period, graft and patient survival were significantly higher with (induction–last follow-up immunosuppressive regimen available) PR–PR than with IR–IR tacrolimus (88% vs 82% at 4 years, $p = 0.019$ and 89% vs 83% at 4 years, $p = 0.047$, respectively) (**Figure 4**). Patients converted from IR to PR tacrolimus after 1 month had a significantly higher graft and patient survival rate compared with patients who were started on and still receiving PR tacrolimus at the last follow-up (92% vs 88% at 4 years, $p = 0.019$ and 94% vs 89% at 4 years, $p = 0.004$, respectively) or started on and still receiving IR tacrolimus at the last follow-up ($p < 0.001$ for both).

Causes of graft loss and mortality

The most common cause of graft loss was infection in both groups (**Table 5**). Over 8 years of treatment, the proportion of patients with bacterial infection that resulted in graft loss was higher with PR versus IR tacrolimus (17.2% vs 9.2%, respectively; $p = 0.031$) (**Table 5**).

Compared with patients receiving IR tacrolimus, ‘other’ causes of graft loss were less

frequent in patients receiving PR tacrolimus ($p=0.01$). However, there were no significant differences between groups in the incidence of graft loss due to acute or chronic rejection, cardiovascular, or renal causes.

The most common cause of patient mortality was infection in both groups (**Table 5**). The proportion of patients with bacterial infection that resulted in patient death was similar with PR and IR tacrolimus (18.3% vs 10.4%, respectively; $p=0.057$). ‘Other’ causes of mortality were less frequent in patients receiving PR versus IR tacrolimus ($p=0.005$). There were no significant differences between treatment groups in the proportion of patients with cardiovascular or renal causes of mortality.

Discussion

The initial ELTR study was the first large retrospective registry study in Europe, evaluating PR tacrolimus-based immunosuppression in primary liver transplantation.²¹ The study showed that the use of IR tacrolimus was associated with a higher risk of graft loss and patient death, compared with PR tacrolimus. Additionally, PR tacrolimus significantly improved graft and patient survival over 3 years post transplantation, compared with the IR formulation.²¹ However, the cohort size was relatively limited, as was the length of follow-up.

This extension to the ELTR study, reporting up to 8-year data from adult primary liver transplant recipients, confirmed that PR tacrolimus was associated with improved graft and patient survival (over 4 years post transplantation), compared with IR tacrolimus. Consistent with Adam et al, IR tacrolimus was an independent risk factor for graft loss and mortality over 8 years of treatment.²¹ In addition to the longer time period assessed, the number of patients included in the current study exceeded 13,000, compared with the 4367 patients included in the initial ELTR study.²¹ This provided enhanced statistical robustness, increasing the reliability of the results.

Univariate and multivariate analyses substantiated the independent prognostic value of typical risk factors, including donor age (≥ 50 years), recipient viral status (HCV-positivity) and UNOS status 1 or 2 in impairing Month 1 to Year 8 graft and patient survival.^{25,26} As reported by Adam et al,²¹ IR tacrolimus was also identified in this study as a significant predictor of graft loss and patient death in univariate analyses. Furthermore, after accounting for differences in baseline characteristics between treatment groups, IR tacrolimus formulation remained a significant predictor of graft and patient loss, in both univariate and multivariate analyses.

In the previous ELTR study, improvements in graft and patient survival with PR versus IR tacrolimus were observed as early as 3 months after transplantation, and continued over 3 years.²¹ Our current data demonstrate that the survival benefit associated with PR tacrolimus continues over 4 years of treatment. Furthermore, while improved 3-year patient survival with PR versus IR tacrolimus did not reach statistical significance for the unmatched patient cohort in the initial ELTR study,²¹ the benefit was statistically significant by Year 4 in our current study. Indeed, there was a 5% and 4% graft and patient survival advantage, respectively, by Year 4 with the PR versus IR formulation. The difference between the PR and IR groups for graft and patient survival rates also seemed to increase with time.

Consistent with data reported in a 4-year follow-up of de novo liver transplant recipients from a Phase II study,²⁷ PR tacrolimus was associated with 4-year graft and patient survival rates of ~90%. As a complement to our previous study, we also evaluated the impact of crossover changes from IR to PR and vice versa after 1 month of induction therapy with regards to graft and patient outcomes. Both graft and patient survival were higher in patients who converted from IR to PR tacrolimus, compared with those who received induction PR tacrolimus and were still receiving PR tacrolimus at last follow-up. While the cause of this is unclear, the data suggest that the use of PR tacrolimus at last follow-up therapy is associated with

improved outcomes, irrespective of the timing of conversion. The transplant community is now interested in identifying whether earlier conversion (<6 months after liver transplantation) from IR to PR tacrolimus is associated with better outcomes than conversion >6 months post transplantation.²⁸

The survival advantages observed in patients treated with PR versus IR tacrolimus reported at 3 years in Adam et al,²¹ and at 4 years in this study, were not observed in short-term, randomized, controlled trials. For example, Trunečka et al reported 12-month graft survival rates of 85.3% and 85.6%, and patient survival rates of 89.2% and 90.8%, with PR and IR tacrolimus, respectively.²⁹ The potential survival advantages associated with PR tacrolimus in de novo liver transplant recipients may, therefore, not become apparent until beyond 1-year post transplantation.

In an independent Editorial that accompanied the initial ELTR study, Asrani et al³⁰ considered the potential mechanisms underlying the improvement in long-term graft and patient survival with PR versus IR tacrolimus-based immunosuppression. Compared with IR tacrolimus, PR formulation reduces variability of tacrolimus exposure,^{19,31} and offers a simpler regimen comprising a single, morning dose,¹² which can improve medication adherence.^{17,18} Indeed, in an expert literature review, improved adherence with treatment is highlighted as a main advantage of PR versus IR tacrolimus.²⁸ Given that high intra-patient variability in tacrolimus exposure and medication non adherence have been associated with poor transplant outcomes,^{8,20} PR tacrolimus may improve long-term graft and patient survival compared with the IR formulation.

As observed in the initial ELTR study,²¹ the overall proportion of patients with graft loss was lower in the PR versus IR tacrolimus group. The reasons for graft loss and mortality were generally comparable between groups in this study and, consistent with the previous ELTR study, infections were the most frequent cause.²¹

In this study, not all factors could be controlled by the transplant team in order to improve outcomes. Only the type of preservation solution, the ischemia time, and the immunosuppressive regimen used could be altered, as donor and recipient characteristics cannot be changed in the MELD allocation system used in most countries. Therefore, it is important to consider the numbers of patients needed to treat with PR tacrolimus in order to avoid one graft loss. In this study, 14.3 patients needed to be treated with PR versus IR tacrolimus in order to avoid one graft loss in 4 years. These data are consistent with those of Muduma et al, who developed a model using UK liver transplant data and showed that, over a 3-year time period, one graft would be saved for every 14 patients treated with PR versus IR tacrolimus, with minimal impact on costs.³² To place these data in clinical context, 15 patients needed to be treated with nicotine replacement therapy for one patient to cease smoking,³³ 20 required treatment with calcium and vitamin D for 3 years to prevent one hip fracture,³⁴ 23 required treatment with flu vaccine to prevent one flu episode,³⁵ and 35 needed primary treatment with statins for 5 years to prevent a cardiac event.³⁶

Despite the improvements to our study design and analytical methods, any conclusions drawn from our findings must be made within the context of the limitations of our study, which have been described in detail previously.²¹ These include the retrospective nature of the study, and the long period over which data were collected, which may be associated with changes in clinical practice. Furthermore, our study design carries a risk of bias in terms of patient and treatment selection. To control for these differences, propensity score-matching was undertaken against a larger number of characteristics compared with the initial ELTR study. However, it is recognized that propensity-score matching can only be used to balance measured variables and cannot entirely exclude inherent differences, such as socioeconomic factors, ethnicity, or other unknown variables. A major limitation concerns the lack of data on drug exposure, as the dose and trough levels of tacrolimus were not captured in the ELTR; it

is also not known which IR tacrolimus preparation patients were receiving. Despite these limitations, to our knowledge, we report on the largest population of liver transplant recipients to date, comparing the impact of PR and IR tacrolimus administration.

Furthermore, this analysis builds on our previous publication by including a three-fold larger cohort, providing extended follow-up, evaluating the impact of crossover between IR and PR tacrolimus therapy, and reporting the clinical implication of the results in terms of number needed to treat to avoid one graft loss.

Our results, based on up to 8-year data, confirm observations from the initial 3-year study,²¹ that PR tacrolimus-based immunosuppression can improve long-term outcomes in liver transplantation compared with IR tacrolimus. Furthermore, IR tacrolimus-based immunosuppression is a significant predictor of long-term graft loss and patient mortality. Conversion from IR to PR tacrolimus after 1 month was also associated with a better outcome compared with maintaining patients on IR tacrolimus-based immunosuppression, or starting and maintaining patients on PR tacrolimus-based immunosuppression. Importantly, our findings confirm that PR tacrolimus continues to provide ongoing benefits for graft and patient survival beyond 3 years post transplantation.

ACKNOWLEDGMENTS: Thanks to all the centers who contribute to the ELTR. The Organ Sharing Organizations the French ABM (Sami Djabbour and Alain Jolly), the Dutch NTS (Cynthia Konijn), the Eurotransplant Foundation (Marieke Van Meel and Erwin de Vries), the Spanish ONT (Gloria de la Rosa), and the UK–Ireland NHSBT (Mike Chilton and Julia Micciche) are acknowledged for the data cross-check and sharing with the ELTR. Astellas is acknowledged for the initial idea of the analysis, and for participation in further scientific discussion. Daniella T Draper, PhD, CMPP and Anna Thompson, PhD from Cello Health MedErgy (Europe) assisted in drafting the initial version of the manuscript under the

direction of the authors, and provided editorial support throughout its development. Editorial support was funded by a grant from Astellas Pharma, Inc.

ACCEPTED

REFERENCES

1. European Liver Transplant Registry. Donor data. www.eltr.eu. Published 2015.
2. European Liver Transplant Registry. Mortality and retransplantation. www.eltr.eu. Published 2015.
3. Gambato M, Frigo AC, Rodríguez Castro KI, et al. Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study. *Transplantation*. 2013;95(12):1528-1534.
4. Onaca NN, Levy MF, Sanchez EQ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. *Liver Transpl*. 2003;9:117-123.
5. Mor E, Gonwa T, Husberg BS, et al. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. *Transplantation*. 1992;54(5):821-824.
6. Berlakovich GA, Langer F, Freundorfer E, et al. General compliance after liver transplantation for alcoholic cirrhosis. *Transpl Int*. 2000;13(2):129-135.
7. O'Carroll RE, McGregor LM, Swanson V, et al. Adherence to medication after liver transplantation in Scotland: a pilot study. 2006;12(12):1862-1868.
8. Lieber SR, Volk ML. Non-adherence and graft failure in adult liver transplant recipients. *Dig Dis Sci*. 2013;58(3):824-834.
9. Cervelli M, Russ G. Inpatient variability with tacrolimus. *Aust J Pharm*. 2012;93(1103):83-86.
10. Burra P, Germani G, Gnoato F, et al. Adherence in liver transplant recipients. *Liver Transpl*. 2011;17(7):760-770.
11. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 Annual Data Report: Liver. *Am J Transplant*. 2017;17 Suppl 1:174-251.

12. Advagraf European Public Assessment Reports (EPAR). European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000712/WC500022237.pdf. Published 2007. Accessed February 2019.
13. Trunečka P, Klempnauer J, Bechstein WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study. *Am J Transplant*. 2015;15(7):1843-1854.
14. Dumortier J, Guillaud O, Boillot O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. *Liver Transpl*. 2013;19(5):529-533.
15. Shamilin S, Ranju M, Bismi ES, et al. A comparative study of once daily versus twice daily tacrolimus in liver transplantation. *J Young Pharm*. 2017;9(4):605-609.
16. Altieri M, Delaval G, Kimmoun E, et al. Conversion from once-daily prolonged-release tacrolimus to once-daily extended-release tacrolimus in stable liver transplant recipients. *Exp Clin Transplant*. 2018;16(3):321-325.
17. Beckebaum S, Jacob S, Sweid D, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. *Transpl Int*. 2011;24(7):666-675.
18. Valente G, Rinaldi L, Sgambato M, et al. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. *Transplant Proc*. 2013;45(3):1273-1275.
19. Saňko-Resmer J, Boillot O, Wolf P, et al. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. *Transpl Int*. 2012;25(3):283-293.

20. Supelana C, Annunziato RA, Schiano TD, et al. Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. *Liver Transpl.* 2014;20(10):1168-1177.
21. Adam R, Karam V, Delvart V, et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. *Am J Transplant.* 2015;15(5):1267-1282.
22. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol.* 2012;57(3):675-688.
23. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. *Nephrol Dial Transplant.* 2003;18 Suppl 1:i7-i11.
24. Burra P, Senzolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant.* 2010;10(1):138-148.
25. Cuervas-Mons V, de la Rosa G, Pardo F, et al. Activity and results of liver transplantation in Spain during 1984-2012. Analysis of the Spanish Liver Transplant Registry. *Med Clin (Barc).* 2015;144(8):337-347.
26. Gwiasda J, Schrem H, Klempnauer J, et al. Identifying independent risk factors for graft loss after primary liver transplantation. *Langenbeck's Arch Surg.* 2017;402(5):757-766.
27. van Hooff JP, Alloway RR, Trunečka P, et al. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. *Clin Transplant.* 2011;25(1):E1-12.

28. Coilly A, Calmus Y, Chermak F, et al. Once-daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations. *Liver Transpl.* 2015;21(10):1312-1321.
29. Trunečka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. *Am J Transpl.* 2010;10(10):2313-2323.
30. Asrani SK, O'Leary JG. Can one pill a day keep rejection away? *Am J Transplant.* 2015;15(5):1135-1136.
31. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. *Transplant Proc.* 2005;37(2):1211-1213.
32. Muduma G, Odeyemi I, Pollock RF. Evaluating the cost-effectiveness of prolonged-release tacrolimus relative to immediate-release tacrolimus in liver transplant patients based on data from routine clinical practice. *Drugs Real World Outcomes.* 2016;3(1):61-68.
33. Green G. Nicotine replacement therapy for smoking cessation. The NNT Group. www.thennt.com/nnt/nicotine-replacement-therapy-for-smoking-cessation. Published May 1, 2013. Accessed July 20, 2011.
34. Calcium and vitamin D for preventing hip fractures. Bandolier. <http://www.bandolier.org.uk/Conflicts%20Folder/b37-4.html>. Accessed February 2019.
35. Influenza vaccination in the elderly. Bandolier. <http://www.bandolier.org.uk/band11/b11-5.html>. Accessed February 2019.
36. Statins. Bandolier. <http://www.bandolier.org.uk/band47/b47-2.html>. Published 1998. Accessed February 2019.

FIGURE LEGENDS:

Figure 1: Patient populations

*Analysis only in centers using PR tacrolimus and IR tacrolimus. [†]Propensity score-matching ratio 1:2, PR tacrolimus: IR tacrolimus. IR: immediate-release; mITT: modified intent-to-treat; PR: prolonged-release

Figure 2: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of treatment with PR tacrolimus compared with IR tacrolimus, after exclusion of patients with <1 month of follow-up (mITT population)

IR: immediate-release; mITT: modified intent-to-treat; PR: prolonged-release

Figure 3: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of treatment in with PR tacrolimus compared with IR tacrolimus for the propensity score-matched patients

IR: immediate-release; PR: prolonged-release

Figure 4: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of treatment in crossover groups for the propensity score-matched patients

IR: immediate-release; PR: prolonged-release

TABLES

Table 1: Baseline characteristics of donors and liver transplant recipients

Parameter	Category	mITT population			Propensity score-matched patients*			
		PR tacrolimus	IR tacrolimus	p value [†]	PR tacrolimus	IR tacrolimus	p value [†]	
		(n=1762) [‡]	(n=11,326) [‡]		(n=1002) [‡]	(n=2004) [‡]		
Donor characteristics								
Mean (SD) age, years		52.1 (18.7)	51.8 (18.1)	0.49	53.0 (18.7)	53.5 (18.7)	0.56	
		(n=1743)	(n=11,018)					
	≥60 years, n (%)	666 (38.2)	3923 (35.6)	0.035	401 (40.0)	806 (40.2)	0.92	
	≥65 years, n (%)	486 (27.9)	2933 (26.6)	0.27	294 (29.3)	631 (31.5)	0.23	
	≥75 years, n (%)	198 (11.4)	1188 (10.8)	0.47	135 (13.5)	284 (14.2)	0.60	
	Sex, n (%)	Female	754 (43.3)	4874 (44.5)	0.34	449 (45.0)	876 (44.0)	0.57
	Male	987 (56.7)	6072 (55.5)		548 (55.0)	1117 (56.0)		
Recipient characteristics								
Age at first transplant, years	Mean (SD)	53.7 (11.2)	52.3 (11.6)	<0.001	53.1 (11.4)	53.3 (10.8)	0.68	
	≥60 years, n (%)	584 (33.1)	3176 (28)	<0.001	308 (30.7)	603 (30.1)	0.72	
	≥65 years, n (%)	242 (13.7)	1169 (10.3)	<0.001	115 (11.5)	223 (11.1)	0.78	
	≥70 years, n (%)	31 (1.8)	135 (1.2)	0.048	22 (2.2)	22 (1.1)	0.018	
Sex, n (%)	Female	571 (32.4)	3783 (33.4)	0.41	328 (32.7)	623 (31.1)	0.36	
	Male	1191 (67.6)	7542 (66.6)		674 (67.3)	1381 (68.9)		
Mean (SD) BMI, kg/m ²		25.9 (4.7)	25.9 (4.8)	0.97	25.8 (4.8)	25.6 (4.5)	0.20	
		(n=1660)	(n=10,714)		(n=970)	(n=1934)		

Recipient health status and indication for transplant

HBsAg, n (%)	Negative	1486 (91.1)	9130 (87.9)	<0.001	908 (90.6)	1810 (90.3)	0.79
	Positive	146 (8.9)	1261 (12.1)		94 (9.4)	194 (9.7)	
HBV DNA, n (%)	Negative	422 (92.3)	3613 (89.7)	0.079	316 (92.7)	605 (92.2)	0.80
	Positive	35 (7.7)	413 (10.3)		25 (7.3)	51 (7.8)	
Co-existing HBV and delta virus, n (%)	Negative	316 (91.9)	1956 (87.3)	0.016	202 (92.7)	373 (86.9)	0.029
	Positive	28 (8.1)	284 (12.7)		16 (7.3)	56 (13.1)	
Anti-HCV serology, n (%)	Negative	1230 (76.1)	7798 (75.3)	0.48	762 (77.4)	1431 (72.9)	0.008
	Positive	387 (23.9)	2564 (24.7)		222 (22.6)	532 (27.1)	
HCV RNA, n (%)	Negative	292 (61.9)	2699 (66.8)	0.03	217 (63.8)	466 (63.2)	0.85
	Positive	180 (38.1)	1339 (33.2)		123 (36.2)	271 (36.8)	
HIV serology, n (%)	Negative	1179 (98.1)	9821 (98.5)	0.24	825 (97.7)	1805 (98.6)	0.12
	Positive	23 (1.9)	147 (1.5)		19 (2.3)	26 (1.4)	
Main indication for transplant, n (%)	Acute liver disease	111 (6.4)	631 (5.8)	<0.001	62 (6.3)	80 (4.1)	0.046
	Malignant tumors	501 (28.8)	2637 (24.0)		246 (24.9)	511 (25.9)	
	Chronic liver disease	1004 (57.7)	6694 (61.0)		600 (60.7)	1224 (62.1)	
	Benign tumors	45 (2.6)	244 (2.2)		27 (2.7)	36 (1.8)	
	Metabolic diseases	64 (3.7)	583 (5.3)		46 (4.7)	95 (4.8)	
	Other	16 (0.9)	178 (1.6)		8 (0.8)	26 (1.3)	

HCC (primary or secondary disease), n (%)	No	1210 (69.1)	8163 (72.5)	0.003	715 (71.4)	1397 (69.7)	0.35
	Yes	542 (30.9)	3092 (27.5)		287 (28.6)	607 (30.3)	
Criteria for first liver transplant							
Liver transplant urgency [§] , n (%)	Yes	99 (7.0)	701 (7.7)	0.35	65 (9.1)	99 (7.0)	0.093
	No	1309 (93.0)	8346 (92.3)		651 (90.9)	1311 (93.0)	
UNOS status**, n (%)	1	110 (6.7)	1026 (9.7)	<0.001	77 (7.7)	170 (8.5)	0.76
	2	176 (10.7)	1505 (14.2)		141 (14.1)	272 (13.6)	
	3	765 (46.4)	5848 (55.0)		594 (59.3)	1162 (58.0)	
	4	596 (36.2)	2245 (21.1)		190 (19.0)	400 (20.0)	
Mean (SD) MELD score		17.1 (8.5) (n=1725)	17.9 (9.0) (n=11,040)	<0.001	17.6 (8.9)	17.6 (8.8)	0.97
Liver function and baseline laboratory values							
Child-Pugh class, n (%)	A	100 (16.2)	899 (14.1)	0.085	73 (16.6)	165 (16.1)	0.82
	B	279 (45.1)	3166 (49.6)		203 (46.2)	492 (48.0)	
	C	240 (38.8)	2322 (36.4)		163 (37.1)	367 (35.8)	
Mean (SD) serum creatinine concentration, mg/dL		1.1 (1.5) (n=1742)	1.2 (3.8) (n=11,078)	0.23	1.1 (1.8) (n=999)	1.1 (0.9) (n=1993)	0.97
Mean (SD) total bilirubin, mg/dL		5.7 (8.2) (n=1718)	6.2 (9.0) (n=11,038)	0.032	6.1 (8.6) (n=999)	5.9 (8.7) (n=1999)	0.44
Preservation solution, n (%)	HTK	816 (47.1)	3059 (28.0)	<0.001	380 (37.9)	691 (34.5)	0.063
	Other	915 (52.9)	7863 (72.0)		622 (62.1)	1313 (65.5)	

Induction immunosuppressive regimen

Corticosteroids, n (%)	Yes	1219 (69.2)	6959 (61.4)	<0.001	777 (77.5)	1579 (78.8)	0.43
	No	543 (30.8)	4367 (38.6)		225 (22.5)	425 (21.2)	
Azathioprine, n (%)	Yes	9 (0.5)	358 (3.2)	<0.001	7 (0.7)	7 (0.3)	0.18
	No	1753 (99.5)	10,968 (96.8)		995 (99.3)	1997 (99.7)	
Ciclosporin, n (%)	Yes	4 (0.2)	180 (1.6)	<0.001	4 (0.4)	10 (0.5)	0.70
	No	1758 (99.8)	11,146 (98.4)		998 (99.6)	1994 (99.5)	
Everolimus, n (%)	Yes	133 (7.5)	280 (2.5)	<0.001	49 (4.9)	128 (6.4)	0.10
	No	1629 (92.5)	11,046 (97.5)		953 (95.1)	1876 (93.6)	
Basiliximab, n (%)	Yes	387 (22.0)	2875 (25.4)	0.002	274 (27.3)	518 (25.8)	0.38
	No	1375 (78.0)	8451 (74.6)		728 (72.7)	1486 (74.2)	
Sirolimus, n (%)	Yes	3 (0.2)	66 (0.6)	0.026	1 (0.1)	1 (0.0)	0.62
	No	1759 (99.8)	11,260 (99.4)		1001 (99.9)	2003 (100.0)	
MMF, n (%)	Yes	1323 (75.1)	6316 (55.8)	<0.001	762 (76.0)	1504 (75.0)	0.55
	No	439 (24.9)	5010 (44.2)		240 (24.0)	500 (25.0)	
Daclizumab, n (%)	Yes	31 (1.8)	87 (0.8)	<0.001	23 (2.3)	47 (2.3)	0.93
	No	1731 (98.2)	11,239 (99.2)		979 (97.7)	1957 (97.7)	
Mean (SD) length of follow-up, months		25.6 (21.1)	31.5 (26.0)	<0.001	24.4 (19.9)	33.7 (25.4)	<0.001

*Propensity-score matching was based on recipient age (≥ 60 versus < 60 years), donor age (≥ 60 versus < 60 years), full-size organ from a donor after brain death versus all other alternative grafts (living donor, domino, donation after circulatory death, or split grafts from a donor after brain death), MELD score (> 24 versus ≤ 24), recipient hepatitis B virus surface antigen, HCC, presence of severe ascites before liver transplantation, UNOS status (3–4 versus 1–2), total ischemia time (≥ 6 versus < 6 hours), graft preservation solution HTK versus all other

solutions (University Wisconsin, Belzer, Celsior, IGL-1, Marshall, Ringer, SCOT, or other) and administration of other immunosuppressive medications early post transplantation (corticosteroids, MMF, ciclosporin, basiliximab, daclizumab, sirolimus, everolimus, azathioprine). [†]p value between treatment cohort comparisons. [‡]Data were not available for all patients; therefore, percentages are calculated based on available data. [§]Liver transplant urgency was determined by the treating physician, and indicated on the questionnaire by 'yes' or 'no' tick box. ^{**}UNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function. BMI: body mass index; HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HTK: Histidine Tryptophan Ketoglutarate; IR, immediate-release; MELD: Model for End-stage Liver Disease; mITT: modified intent-to-treat; MMF: mycophenolate mofetil; PR: prolonged-release; SD: standard deviation; UNOS: United Network for Organ Sharing

Table 2: Univariate analyses of risk factors for reduced graft and patient survival 1, 2, and 4 years post transplantation, after exclusion of patients with <1 month of follow-up (mITT population)

Parameters at first transplantation	Category	n	Survival, %			p value*
			1 year	2 years	4 years	
Graft survival						
Immunotherapy during Month 1	PR tacrolimus	1762	93	89	84	<0.001
	IR tacrolimus	11,326	91	86	79	
Donor characteristics						
Donor sex	Female	5628	91	86	79	0.51
	Male	7059	91	87	79	
Donor age ≥50 years	Yes	7272	90	85	77	<0.001
	No	5488	93	89	83	
Donor age ≥60 years	Yes	4589	90	84	76	<0.001
	No	8171	92	88	81	
Macro/micro-vesicular graft steatosis	No	3286	93	89	82	0.11
	Yes	2947	91	88	80	
Blood group compatibility	Compatible	794	88	83	77	<0.001
	Iso group	11,983	91	87	80	
	Non compatible	113	77	72	59	
Recipient characteristics						
Recipient sex	Female	4354	92	88	81	<0.001
	Male	8733	91	86	78	
Recipient age ≥50 years	Yes	8693	90	86	78	<0.001

	No	4395	92	89	82	
Recipient age ≥60 years	Yes	3760	89	85	77	<0.001
	No	9328	92	88	81	
Recipient dialysis (twice in week prior)	Yes	442	81	78	71	<0.001
	No	11,177	92	87	80	
Recipient viral status						
HBsAg	Negative	10,616	91	87	79	0.008
	Positive	1407	94	88	83	
Co-existing HBV and delta virus	Negative	2272	90	85	79	0.001
	Positive	312	96	93	91	
Anti-HCV serology	Negative	9028	92	89	82	<0.001
	Positive	2951	88	82	72	
HIV serology	Negative	11,000	91	87	80	<0.001
	Positive	170	82	71	61	
HCV RNA	Negative	2991	92	88	83	<0.001
	Positive	1519	88	83	71	
Criteria for liver transplant						
Liver transplant urgency [†]	Yes	800	89	86	81	0.74
	No	9655	91	87	80	
UNOS status [‡]	1	1136	87	83	77	<0.001
	2	1681	88	84	78	
	3	6613	92	88	80	
	4	2841	93	88	80	

UNOS status [‡] 1 or 2	Yes	2817	87	84	78	<0.001
	No	9454	92	88	80	
MELD score	≤14	5571	93	87	79	<0.001
	15–25	4938	92	88	82	
	>25	2256	87	83	76	
Liver function and laboratory values						
Recipient Child-Pugh class	A	999	92	88	79	0.1
	B	3445	94	90	82	
	C	2562	91	88	80	
Serum creatinine concentration ≥2 mg/dL	Yes	906	83	79	73	<0.001
	No	11,914	92	88	80	
Indication						
Main indication for transplant	Acute liver failure	742	90	86	81	<0.001
	Chronic liver	7698	91	87	80	
	disease					
	Metabolic disease	647	90	87	80	
	Tumor (benign)	289	94	92	88	
	Tumor (malignant)	3138	92	85	76	
	Other	194	87	83	79	
Acute liver failure as main disease	Yes	725	90	86	81	0.2
	No	12,282	91	87	79	
Cirrhosis as main disease	Yes	6935	91	87	80	0.9
	No	6072	91	86	79	

Cancer as main disease	Yes	3133	92	85	76	<0.001
	No	9874	91	87	81	
Milan criteria (in patients with HCC)	Yes	1613	93	88	81	<0.001
	No	808	87	76	61	
HCC with tumor size >50 mm	Yes	214	82	65	48	<0.001
	No	2228	91	86	76	
Surgical procedure						
Total ischemia time	>15 hours	103	90	88	83	0.25
	12–15 hours	623	89	84	78	
	6–12 hours	8325	91	87	79	
	0–6 hours	2409	92	86	80	
Total ischemia time ≥12 hours	Yes	726	89	85	78	0.53
	No	10,734	91	87	79	
Type of graft	Full size (donor brain death)	11,390	91	87	79	0.4
	Domino	89	91	84	70	
	Living	520	91	83	75	
	Reduced	36	88	88	88	
	Split	526	90	88	82	
	After circulatory death	486	93	87	80	
Liver transplant	Heterotopic	15	100	88	72	0.67
	Orthotopic	12,424	91	87	80	

Patient survival						
Immunotherapy during Month 1	PR tacrolimus	1762	94	90	85	0.003
	IR tacrolimus	11,319	92	88	81	
Donor characteristics						
Donor sex	Female	5623	92	88	81	0.48
	Male	7057	92	88	82	
Donor age ≥50 years	Yes	7268	91	87	79	<0.001
	No	5485	94	90	85	
Donor age ≥60 years	Yes	4587	91	86	78	<0.001
	No	8166	93	89	84	
Macro/micro-vesicular graft steatosis	No	3284	94	91	85	0.01
	Yes	2943	92	89	82	
Blood group compatibility	Compatible	793	89	84	78	<0.001
	Iso group	11,977	92	89	82	
	Non compatible	113	80	77	63	
Recipient characteristics						
Recipient sex	Female	4353	93	90	84	<0.001
	Male	8727	92	88	81	
Recipient age ≥50 years	Yes	8689	91	87	80	<0.001
	No	4392	94	91	85	
Recipient age ≥60 years	Yes	3758	90	86	78	<0.001
	No	9323	93	89	83	
Recipient dialysis (twice in week	Yes	442	82	79	74	<0.001

prior)	No	11,170	93	89	83	
Recipient viral status						
HBsAg	Negative	10,612	92	88	82	0.007
	Positive	1406	95	90	85	
Co-existing HBV and delta virus	Negative	2272	91	86	80	<0.001
	Positive	312	96	94	92	
Anti-HCV serology	Negative	9023	93	90	84	<0.001
	Positive	2949	89	84	75	
HIV serology	Negative	10,995	93	89	82	<0.001
	Positive	169	82	74	64	
HCV RNA	Negative	2991	93	90	85	<0.001
	Positive	1518	90	84	74	
Criteria for liver transplant						
Liver transplant urgency [†]	Yes	800	90	88	86	0.43
	No	9648	93	89	82	
UNOS status [‡]	1	1135	88	85	81	<0.001
	2	1680	89	85	80	
	3	6612	94	90	82	
	4	2837	94	90	83	
UNOS status [‡] 1 or 2	Yes	2815	88	85	80	<0.001
	No	9449	94	90	83	
MELD score	≤14	5569	94	89	81	<0.001
	15–25	4934	93	90	84	

	>25	2255	88	85	79	
Liver function and laboratory values						
Recipient Child-Pugh class	A	999	95	90	82	0.05
	B	3442	95	91	85	
	C	2560	92	89	84	
Serum creatinine concentration	Yes	905	84	80	75	<0.001
≥2 mg/dL	No	11,908	93	89	82	
Indication						
Main indication for transplant	Acute liver failure	742	90	87	85	<0.001
	Chronic liver	7694	92	89	82	
	disease					
	Metabolic disease	647	91	88	82	
	Tumor (benign)	289	95	94	91	
	Tumor (malignant)	3138	93	86	77	
	Other	194	89	86	80	
Acute liver failure as main disease	Yes	725	90	87	85	0.16
	No	12,275	92	88	81	
Cirrhosis as main disease	Yes	6931	92	89	82	0.63
	No	6069	93	88	81	
Cancer as main disease	Yes	3133	93	86	77	<0.001
	No	9867	92	89	83	
Milan criteria (in patients with HCC)	Yes	1613	94	89	83	<0.001
	No	808	88	77	62	

HCC with tumor size >50 mm	Yes	214	82	66	50	<0.001
	No	2228	93	87	78	
Total ischemia time	>15 hours	103	90	88	85	0.59
	12–15 hours	622	91	87	81	
	6–12 hours	8319	92	89	82	
	0–6 hours	2409	93	88	82	
Total ischemia time ≥12 hours	Yes	725	91	87	81	0.94
	No	10,728	92	88	82	
Type of graft	Full size (donor brain death)	11,387	92	88	81	0.005
	Domino	89	91	87	73	
	Living	520	92	84	78	
	Reduced	36	100	96	96	
	Split	526	93	90	86	
	After circulatory death	482	96	91	85	
Liver transplant	Heterotopic	15	100	88	72	0.5
	Orthotopic	12,417	92	89	82	

*Log-rank p value for effect over 8 years. †Liver transplant urgency was determined by the treating physician, and indicated on the questionnaire by 'yes' or 'no' tick box. ‡UNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function. HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular

carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IR: immediate-release; MELD: Model for End-stage Liver Disease; mITT: modified intent-to-treat; PR: prolonged-release; UNOS: United Network for Organ Sharing

Table 3: Univariate analyses of risk factors for reduced graft and patient survival for propensity score-matched patients

Parameters at first transplant	Category	n	Survival, %			p value*
			1 year	2 years	4 years	
Graft survival						
Immunotherapy during Month 1	PR tacrolimus	1002	93	89	83	0.005
	IR tacrolimus	2004	90	86	77	
Donor characteristics						
Donor sex	Female	1325	92	87	79	0.55
	Male	1665	91	88	80	
Donor age ≥50 years	Yes	1776	90	85	76	<0.001
	No	1230	93	90	84	
Donor age ≥60 years	Yes	1207	90	84	75	<0.001
	No	1799	92	89	82	
Macro/micro-vesicular graft steatosis	No	597	93	90	81	0.069
	Yes	604	90	86	77	
Blood group compatibility	Compatible	182	85	81	74	0.19
	Iso group	2799	92	88	79	
	Non compatible	23	85	77	77	
Recipient characteristics						
Recipient sex	Female	951	92	88	80	0.064
	Male	2055	91	87	78	
Recipient age ≥50 years	Yes	2065	91	86	77	0.006
	No	941	93	89	83	

Recipient age ≥60 years	Yes	911	90	85	76	0.016
	No	2095	92	88	80	
Recipient dialysis twice in week prior to transplantation	Yes	124	83	77	73	0.016
	No	2685	92	88	79	
Recipient viral status						
HBsAg	Negative	2718	91	87	79	0.37
	Positive	288	93	88	83	
Co-existing HBV and delta virus	Negative	575	89	84	73	0.017
	Positive	72	98	95	95	
Anti-HCV serology	Negative	2193	92	89	83	<0.001
	Positive	754	88	82	67	
HIV serology	Negative	2630	91	87	79	0.028
	Positive	45	91	76	66	
HCV RNA	Negative	683	91	87	84	<0.001
	Positive	394	88	80	63	
Criteria for liver transplant						
Liver transplant urgency [†]	Yes	164	84	81	79	0.038
	No	1962	92	88	80	
UNOS status [‡]	1	247	88	83	80	<0.001
	2	413	84	79	73	
	3	1756	93	89	81	
	4	590	93	89	77	
UNOS status [‡] 1 or 2	Yes	660	86	81	75	<0.001

	No	2346	93	89	80	
MELD score	≤14	1326	93	88	77	0.47
	15–25	1159	91	87	81	
	>25	521	89	85	79	
Liver function and laboratory values						
Recipient Child-Pugh class	A	238	94	90	82	0.37
	B	695	93	90	81	
	C	530	90	86	79	
Serum creatinine concentration	Yes	185	87	80	74	0.01
≥2 mg/dL	No	2807	92	88	80	
Indication						
Main indication for transplant	Acute liver failure	142	89	85	85	0.45
	Chronic liver disease	1824	91	88	80	
	Metabolic disease	141	89	86	78	
	Tumor (benign)	63	95	88	84	
	Tumor (malignant)	757	93	86	75	
	Other	34	85	85	79	
Acute liver failure as main disease	Yes	140	89	85	85	0.33
	No	2866	92	87	79	
Cirrhosis as main disease	Yes	1648	91	88	79	0.86
	No	1358	92	87	79	
Cancer as main disease	Yes	756	93	86	75	0.1

	No	2250	91	88	80	
Milan criteria (in patients with HCC)	Yes	550	93	87	79	<0.001
	No	224	88	79	60	
HCC with tumor size >50 mm	Yes	63	83	65	46	<0.001
	No	715	92	86	76	
Surgical procedure						
Total ischemia time	>15 hours	17	82	82	82	0.39
	12–15 hours	128	84	79	78	
	6–12 hours	2186	91	87	79	
	0–6 hours	675	93	88	81	
Total ischemia time ≥12 hours	Yes	145	84	80	78	0.47
	No	2861	92	88	79	
Type of graft	Full size (donor brain death)	2712	91	87	79	0.65
	Domino	28	93	85	65	
	Living	77	87	83	83	
	Reduced	13	92	92	92	
	Split	116	93	92	85	
	After circulatory death	60	94	87	87	
Liver transplant	Heterotopic	4	100	67		0.003
	Orthotopic	2857	92	87	79	

Patient survival

Immunotherapy during Month 1	PR tacrolimus	1002	94	90	85	0.017
	IR tacrolimus	2004	92	88	80	
Donor characteristics						
Donor sex	Female	1325	92	87	80	0.18
	Male	1665	93	89	83	
Donor age ≥50 years	Yes	1776	91	86	78	<0.001
	No	1230	94	92	86	
Donor age ≥60 years	Yes	1207	92	86	77	<0.001
	No	1799	93	90	84	
Macro/micro-vesicular graft steatosis	No	597	93	91	85	0.039
	Yes	604	92	88	78	
Blood group compatibility	Compatible	182	85	81	75	0.11
	Iso group	2799	93	89	82	
	Non compatible	23	90	83	83	
Recipient characteristics						
Recipient sex	Female	951	93	90	83	0.021
	Male	2055	92	88	80	
Recipient age ≥50 years	Yes	2065	92	88	79	0.001
	No	941	93	90	86	
Recipient age ≥60 years	Yes	911	91	86	77	0.001
	No	2095	93	89	83	
Recipient dialysis (twice in week prior)	Yes	124	83	77	73	0.002
	No	2685	93	89	82	

Recipient viral status

HBsAg	Negative	2718	92	88	81	0.3
	Positive	288	94	90	85	
Co-existing HBV and delta virus	Negative	575	90	85	76	0.025
	Positive	72	98	95	95	
Anti-HCV serology	Negative	2193	93	90	84	<0.001
	Positive	754	89	83	71	
HIV serology	Negative	2630	92	88	81	0.045
	Positive	45	91	80	70	
HCV RNA	Negative	683	92	89	85	<0.001
	Positive	394	88	81	67	

Criteria for liver transplant

Liver transplant urgency [†]	Yes	164	84	84	81	0.099
	No	1962	93	89	82	
UNOS status [‡]	1	247	89	85	82	<0.001
	2	413	85	81	74	
	3	1756	94	90	83	
	4	590	94	90	80	
UNOS status [‡] 1 or 2	Yes	660	87	83	77	<0.001
	No	2346	94	90	82	
MELD score	≤14	1326	94	89	79	0.22
	15–25	1159	92	89	84	
	>25	521	90	86	80	

Liver function and laboratory values

Recipient Child-Pugh class	A	238	96	91	84	0.27
	B	695	94	91	83	
	C	530	90	87	81	
Serum creatinine concentration ≥2 mg/dL	Yes	185	88	80	75	0.001
	No	2807	93	89	82	

Indication

Main indication for transplant	Acute liver failure	142	90	87	87	0.24
	Chronic liver disease	1824	92	89	82	
	Metabolic disease	141	90	87	78	
	Tumor (benign)	63	95	92	89	
	Tumor (malignant)	757	93	87	77	
	Other	34	91	91	85	
Acute liver failure as main disease	Yes	140	90	87	87	0.34
	No	2866	92	88	81	
Cirrhosis as main disease	Yes	1648	92	89	82	0.61
	No	1358	93	88	81	
Cancer as main disease	Yes	756	93	87	77	0.032
	No	2250	92	89	83	
Milan criteria (in patients with HCC)	Yes	550	94	88	81	<0.001
	No	224	89	80	62	
HCC with tumor size >50 mm	Yes	63	83	66	48	<0.001

	No	715	93	87	78	
Total ischemia time	>15 hours	17	82	82	82	0.31
	12–15 hours	128	85	80	79	
	6–12 hours	2186	92	89	81	
	0–6 hours	675	94	90	83	
Total ischemia time ≥12 hours	Yes	145	85	80	79	0.26
	No	2861	93	89	81	
Type of graft	Full size (donor brain death)	2712	92	88	81	0.57
	Domino	28	93	89	69	
	Living	77	89	89	89	
	Reduced	13	100	100		
	Split	116	94	93	88	
	After circulatory death	60	98	91	86	
Liver transplant	Heterotopic	4	100	67		0.001
	Orthotopic	2857	92	89	81	

*Log-rank p value for effect over 8 years. [†]Body-mass index was defined as underweight: <18.5 kg/m², normal weight: 18.5–24.9 kg/m², overweight: 25.0–29.9 kg/m², obesity: ≥30 kg/m². [‡]Liver transplant urgency was determined by the treating physician and indicated on the questionnaire by ‘yes’ or ‘no’ tick box. [§]UNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function. HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular

carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IR: immediate-release; MELD: Model for End-stage Liver Disease; PR: prolonged-release; UNOS: United Network for Organ Sharing

Table 4. Multivariate analyses of risk factors for reduced graft and patient survival for the propensity score-matched patients

Risk factors at first transplant	Risk ratio	95% confidence interval	p value
Graft survival			
Recipient anti-HCV serology positive	2.05	1.66–2.54	<0.001
Recipient age ≥55 years	1.74	1.43–2.11	<0.001
UNOS status* 1 or 2	1.69	1.35–2.11	<0.001
Serum creatinine concentration ≥2 mg/dL	1.66	1.18–2.35	0.004
IR tacrolimus immunotherapy	1.49	1.14–1.96	0.0038
Donor age ≥50 years	1.35	1.09–1.66	0.0052
Patient survival			
Recipient anti-HCV serology positive	1.91	1.52–2.40	<0.001
Serum creatinine concentration ≥ 2 mg/dL	1.90	1.33–2.71	<0.001
UNOS status* 1 or 2	1.89	1.49–2.39	<0.001
Recipient age ≥55 years	1.74	1.41–2.16	<0.001
IR tacrolimus immunotherapy	1.40	1.05–1.86	0.0215
HCC (primary or secondary disease)	1.35	1.07–1.69	0.0109
Donor age ≥50 years	1.33	1.07–1.66	0.0110

*UNOS status 1: Hospitalized in the intensive care unit; 2: continuous hospitalization.

N=3,883. HCC: hepatocellular carcinoma; HCV: hepatitis C virus; IR: immediate-release;

UNOS: United Network for Organ Sharing

Table 5: Causes of graft loss and mortality over 8 years of treatment for the propensity score-matched patients

Category	Type	Graft loss, n (%)				Mortality, n (%)			
		All (n=3006)	PR tacrolimus (n=1002)	IR tacrolimus (n=2004)	p value*	All (n=3006)	PR tacrolimus (n=1002)	IR tacrolimus (n=2004)	p value*
Overall		408	93	315	–	351	82	269	–
Technical complications	All	44 (10.8)	12 (12.9)	32 (10.2)	0.45	19 (5.4)	6 (7.3)	13 (4.8)	0.38
	Biliary	21 (5.2)	6 (6.5)	15 (4.8)	0.39	12 (3.4)	4 (4.9)	8 (3.0)	0.41
	Vascular	24 (5.9)	6 (6.5)	18 (5.7)	0.79	8 (2.3)	2 (2.4)	6 (2.2)	1.00
Rejection	All	16 (3.9)	3 (3.2)	13 (4.1)	1.00	8 (2.3)	2 (2.4)	6 (2.2)	1.00
	Acute	5 (1.2)	1 (1.1)	4 (1.3)	1.00	3 (0.9)	1 (1.2)	2 (0.7)	0.55
	Chronic	11 (2.7)	2 (2.2)	9 (2.9)	1.00	5 (1.4)	1 (1.2)	4 (1.5)	1.00
Non tumoral recurrence		76 (18.6)	22 (23.7)	54 (17.1)	0.16	57 (16.2)	19 (23.2)	38 (14.1)	0.06
Other liver complications		13 (3.2)	3 (3.2)	10 (3.2)	1.00	12 (3.4)	3 (3.7)	9 (3.4)	1.00
Tumor	Tumor recurrence	49 (12.0)	13 (14.0)	36 (11.4)	0.51	48 (13.7)	13 (15.9)	35 (13.0)	0.51
	De novo tumor	50 (12.3)	10 (10.8)	40 (12.7)	0.62	50 (14.2)	10 (12.2)	40 (14.9)	0.54
	De novo tumor (lymph)	3 (0.7)	1 (1.1)	2 (0.6)	0.54	3 (0.9)	1 (1.2)	2 (0.7)	0.55
Infection	Overall	109 (26.7)	28 (30.1)	81 (25.7)	0.40	107 (30.5)	27 (32.9)	80 (29.7)	0.58
	Bacterial	45 (11.0)	16 (17.2)	29 (9.2)	0.031	43 (12.3)	15 (18.3)	28 (10.4)	0.057

General	Viral	1 (0.2)	0	1 (0.3)	1.00	1 (0.3)	0	1 (0.4)	1.00
	Fungal	2 (0.5)	1 (1.1)	1 (0.3)	0.40	2 (0.6)	1 (1.2)	1 (0.4)	0.41
	Undefined	67 (16.4)	13 (14.0)	54 (17.1)	0.47	66 (18.8)	12 (14.6)	54 (20.1)	0.27
	Gastrointestinal	13 (3.2)	3 (3.2)	10 (3.2)	1.00	13 (3.7)	3 (3.7)	10 (3.7)	1.00
	Cardiovascular	18 (4.4)	5 (5.4)	13 (4.1)	0.57	18 (5.1)	5 (6.1)	13 (4.8)	0.58
	Cerebrovascular	13 (3.2)	6 (6.5)	7 (2.2)	0.08	13 (3.7)	6 (7.3)	7 (2.6)	0.09
	Renal	15 (3.7)	3 (3.2)	12 (3.8)	1.00	15 (4.3)	3 (3.7)	12 (4.5)	1.00
Other	Pulmonary	31 (7.6)	7 (7.5)	24 (7.6)	0.98	31 (8.8)	7 (8.5)	24 (8.9)	0.91
	Other	66 (16.2)	7 (7.5)	59 (18.7)	0.010	62 (17.7)	6 (7.3)	56 (20.8)	0.005
	Social cause	3 (0.7)	1 (1.1)	2 (0.6)	0.54	3 (0.9)	1 (1.2)	2 (0.7)	0.55
Suicide		1 (0.2)	0	1 (0.3)	1.00	1 (0.3)	0	1 (0.4)	1.00

*p value for Mantel–Haenszel Chi-Square between treatment cohort comparisons, or Fisher’s exact test, as appropriate. Data are presented for up to three causes of graft loss or patient mortality for each patient. IR: immediate-release; PR: prolonged-release

Figure 1

Figure 2a

Figure 2b

Figure 3a

Figure 3b

Figure 4a

Survival, %		1 year	2 years	3 years	4 years
PR-PR		95	93	92	88
PR-IR		98	91	87	87
IR-PR		97	97	93	92
IR-IR		93	89	86	82
Patients at risk	Total				
PR-PR	560	417	270	177	105
PR-IR	176	142	91	45	16
IR-PR	274	254	214	167	124
IR-IR	1074	879	668	486	348

Figure 4b

Survival, %	1 year	2 years	3 years	4 years
PR-PR	95	94	92	89
PR-IR	99	91	90	90
IR-PR	99	98	95	94
IR-IR	94	91	87	83

Patients at risk	Total	1 year	2 years	3 years	4 years
PR-PR	560	418	272	178	106
PR-IR	176	144	92	48	19
IR-PR	274	258	217	168	125
IR-IR	1074	888	679	495	355